History-adjusted marginal structural models for estimating time-varying effect modification

American Journal of Epidemiology

Volumn 166, Issue 9, 2007, Pages 985-993

  Petersen, Maya L ^a   Deeks, Steven G ^b   Martin, Jeffrey N ^b   Van Der Laan, Mark J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretroviral therapy, highly active; Causality; Confounding factors (epidemiology); HIV; Longitudinal studies; Observational data; Structural model; Time dependent covariate

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; ENFUVIRTIDE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

BIOMARKER; COHORT ANALYSIS; DISEASE TREATMENT; EPIDEMIOLOGY; ESTIMATION METHOD; HUMAN IMMUNODEFICIENCY VIRUS; MODEL VALIDATION; OBSERVATIONAL METHOD; STATISTICAL ANALYSIS; TIME SERIES;

ARTICLE; BIOSTATISTICS; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SUBSTITUTION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTORY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; OBSERVATIONAL STUDY; PROGNOSIS; STATISTICAL MODEL; TIME; TREATMENT RESPONSE; UNITED STATES;

ALGORITHMS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DATA INTERPRETATION, STATISTICAL; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; LYMPHOCYTE COUNT; MATHEMATICAL COMPUTING; MODELS, BIOLOGICAL; MODELS, STATISTICAL; ODDS RATIO; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

CALIFORNIA; NORTH AMERICA; SAN FRANCISCO; UNITED STATES;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33947676177     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwm232     Document Type: Article

References (15)

1. Robins JM. Marginal structural models versus structural nested models as tools for causal inference. In: Halloran ME, Berry D, eds. Statistical models in epidemiology, the environment, and clinical trials. New York, NY: Springer-Verlag, 1999:95-134.
2. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-60.
3. Robins JM. Robust estimation in sequentially ignorable missing data and causal inference models. In: 1999 Proceedings of the American Statistical Association, Section on Bayesian Statistical Science. Alexandria, VA: American Statistical Association, 2000:6-10.
4. Joffe M, Santanna J, Feldman H. Partially marginal structural models for causal inference. (Abstract). Am J Epidemiol 2001;153(suppl):S261.
5. Joffe MM, Knauss J, Robinson B, et al. Lagged partially marginal structural models for controlling confounding. (Abstract). Am J Epidemiol 2004;159(suppl):S66.
6. Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004;15:1623-32.
7. Robins JM. Structural nested failure time models. In: Armitage P, Colton T, eds. The encyclopedia of biostatistics. Chichester, United Kingdom: John Wiley and Sons Ltd, 1998:4372-89.
8. van der Laan MJ, Petersen ML, Joffe MM. History-adjusted marginal structural models and statically-optimal dynamic treatment regimens. Int J Biostat 2005;1:article 4. (Electronic article). (http://www.bepress.com/ijb/ vol1/iss1/4).
9. Panel on Clinical Practices for Treatment of HIV infection, US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: US Department of Health and Human Services, 2005.
10. Deeks SG, Barbour JD, Martin JN, et al. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000;181:946-53.
11. Deeks SG, Barbour JD, Grant RM, et al. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002;16:201-7.
12. Piketty C, Weiss L, Thomas F, et al. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis 2001;183:1328-35.
13. Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003;362:2002-11.
14. van der Laan MJ, Robins JM. Unified methods for censored longitudinal data and causality. New York, NY: Springer-Verlag, 2002:329-47.
15. Sinisi SE, van der Laan MJ. Deletion/substitution/addition algorithm in learning with applications in genomics. Stat Appl Genet Mol Biol 2004;3:article 18. (Electronic article). (http://www.bepress.com/sagmb/vol3/iss1/art18/).